 Ebola Vaccines
"Ebola Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines or candidate vaccines used to prevent EBOLA HEMORRHAGIC FEVER.
| Descriptor ID |
D046129
|
| MeSH Number(s) |
D20.215.894.899.205
|
| Concept/Terms |
Ebola Vaccines- Ebola Vaccines
- Vaccines, Ebola
- Ebola Virus Vaccines
- Vaccines, Ebola Virus
|
Below are MeSH descriptors whose meaning is more general than "Ebola Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Ebola Vaccines".
This graph shows the total number of publications written about "Ebola Vaccines" by people in this website by year, and whether "Ebola Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2012 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2018 | 0 | 1 | 1 | | 2019 | 3 | 0 | 3 | | 2020 | 1 | 0 | 1 | | 2024 | 2 | 0 | 2 | | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Ebola Vaccines" by people in Profiles.
-
Chandrasekaran P, Berry IM, Callier V, Anthony SM, Hensley K, Kuhn JH, Shaw-Saliba K, Kennedy SB, Kieh M, Browne SM, Crozier I, Davey RT, Lane HC, Hensley LE, Follmann DA. Vector-Induced Humoral Responses After rVSV?G-ZEBOV-GP Immunization Identify Vaccinated Individuals and Correlate With Ebola Virus Glycoprotein Antibodies. J Infect Dis. 2025 Oct 15; 232(4):1004-1014.
-
Valayer S, Alexandre M, Prague M, Beavogui AH, Doumbia S, Kieh M, Greenwood B, Leigh B, Poupelin M, Schwimmer C, Sow SO, Berry IM, Kuhn JH, Fusco D, Cauwelaert ND, Watson-Jones D, Thiébaut R, Lévy Y, Yazdanpanah Y, Richert L, Lhomme E. Evaluation of waning of IgG antibody responses after rVSV?G-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial. Emerg Microbes Infect. 2025 Dec; 14(1):0.
-
Davey RT, Collins GL, Rouphael N, Poliquin G, McConnell R, Grubbs G, Moir SL, Langley JM, Teitelbaum M, Hewlett AL, McLellan SLF, Bhadelia N, Raabe VN, Mulligan MJ, Maljkovic Berry I, Dighero-Kemp B, Kurtz JR, Hensley LE, Dozier NCE, Marron LCB, DuChene A, Kuhn JH, Brown SK, Khurana S, Lane HC, Neaton JD. Safety and immunogenicity of a delayed booster dose of the rVSV?G-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial. Lancet Microbe. 2024 Nov; 5(11):100923.
-
Iversen PL, Kane CD, Zeng X, Panchal RG, Warren TK, Radoshitzky SR, Kuhn JH, Mudhasani RR, Cooper CL, Shurtleff AC, Nasar F, Sunay MM, Duplantier AJ, Eaton BP, Zumbrun EE, Bixler SL, Martin S, Meinig JM, Chiang CY, Sanchez-Lockhart M, Palacios GF, Kugelman JR, Martins KA, Pitt ML, Crozier I, Saunders DL. Recent successes in therapeutics for Ebola virus disease: no time for complacency. Lancet Infect Dis. 2020 09; 20(9):e231-e237.
-
Mbala-Kingebeni P, Pratt CB, Wiley MR, Diagne MM, Makiala-Mandanda S, Aziza A, Di Paola N, Chitty JA, Diop M, Ayouba A, Vidal N, Faye O, Faye O, Karhemere S, Aruna A, Nsio J, Mulangu F, Mukadi D, Mukadi P, Kombe J, Mulumba A, Duraffour S, Likofata J, Pukuta E, Caviness K, Bartlett ML, Gonzalez J, Minogue T, Sozhamannan S, Gross SM, Schroth GP, Kuhn JH, Donaldson EF, Delaporte E, Sanchez-Lockhart M, Peeters M, Muyembe-Tamfum JJ, Alpha Sall A, Palacios G, Ahuka-Mundeke S. 2018 Ebola virus disease outbreak in Équateur Province, Democratic Republic of the Congo: a retrospective genomic characterisation. Lancet Infect Dis. 2019 06; 19(6):641-647.
-
Mbala-Kingebeni P, Aziza A, Di Paola N, Wiley MR, Makiala-Mandanda S, Caviness K, Pratt CB, Ladner JT, Kugelman JR, Prieto K, Chitty JA, Larson PA, Beitzel B, Ayouba A, Vidal N, Karhemere S, Diop M, Diagne MM, Faye M, Faye O, Aruna A, Nsio J, Mulangu F, Mukadi D, Mukadi P, Kombe J, Mulumba A, Villabona-Arenas CJ, Pukuta E, Gonzalez J, Bartlett ML, Sozhamannan S, Gross SM, Schroth GP, Tim R, Zhao JJ, Kuhn JH, Diallo B, Yao M, Fall IS, Ndjoloko B, Mossoko M, Lacroix A, Delaporte E, Sanchez-Lockhart M, Sall AA, Muyembe-Tamfum JJ, Peeters M, Palacios G, Ahuka-Mundeke S. Medical countermeasures during the 2018 Ebola virus disease outbreak in the North Kivu and Ituri Provinces of the Democratic Republic of the Congo: a rapid genomic assessment. Lancet Infect Dis. 2019 06; 19(6):648-657.
-
Chisholm CF, Kang TJ, Dong M, Lewis K, Namekar M, Lehrer AT, Randolph TW. Thermostable Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide. Eur J Pharm Biopharm. 2019 Mar; 136:213-220.
-
Warfield KL, Howell KA, Vu H, Geisbert J, Wong G, Shulenin S, Sproule S, Holtsberg FW, Leung DW, Amarasinghe GK, Swenson DL, Bavari S, Kobinger GP, Geisbert TW, Aman MJ. Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms. J Infect Dis. 2018 11 22; 218(suppl_5):S553-S564.
-
Martins KA, Jahrling PB, Bavari S, Kuhn JH. Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines. 2016 09; 15(9):1101-12.
-
Ou W, Delisle J, Jacques J, Shih J, Price G, Kuhn JH, Wang V, Verthelyi D, Kaplan G, Wilson CA. Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain. Virol J. 2012 Jan 25; 9:32.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|